Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma

References

• FerlayJ, SoerjomataramI, ErvikMet al.GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no. 11. Lyon, Fr. Int. Agency Res. Cancer (2013).
   Google Scholar
• ParkinDM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118(12), 3030–3044 (2006).
   PubMed Web of Science ®Google Scholar
• TorreLA, SiegelRL, WardEM, JemalA. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol. Biomarkers Prev.25(1), 16–27 (2016).
   PubMed Web of Science ®Google Scholar
• SakamotoM, MoriT, MasugiY, EffendiK, RieI, DuW. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology51(Suppl. 1), 42–45 (2008).
   PubMedGoogle Scholar
• GallePR, FornerA, LlovetJMet al.EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. (2018).
   Google Scholar
• MarreroJA, KulikLM, SirlinCBet al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology (2018).
   Google Scholar
• OmataM, ChengAL, KokudoNet al.Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int.11(4), 317–370 (2017).
   PubMed Web of Science ®Google Scholar
• DebruyneEN, DelangheJR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin. Chim. Acta395(1-2), 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• CarrBI, AkkizH, UskudarOet al.HCC with low- and normal-serum alpha-fetoprotein levels. Clin. Pract. (Lond).15(1), 453–464 (2018).
   PubMedGoogle Scholar
• TsuchiyaN, SawadaY, EndoI, SaitoK, UemuraY, NakatsuraT. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol.21(37), 10573–83 (2015).
   PubMed Web of Science ®Google Scholar
• GallePR, FoersterF, KudoMet al.Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int.39(12), 2214–2229 (2019).
   PubMed Web of Science ®Google Scholar
• LeeC, KimM, LeeJHet al.COL6A3-derived endotrophin links reciprocal interactions among hepatic cells in the pathology of chronic liver disease. J. Pathol.247(1), 99–109 (2019).
   PubMed Web of Science ®Google Scholar
• KarsdalMA, NielsenSH, LeemingDJet al.The good and the bad collagens of fibrosis – their role in signaling and organ function. Adv. Drug Deliv. Rev.121, 43–56 (2017).
   PubMed Web of Science ®Google Scholar
• UedaJ, YoshidaH, MamadaYet al.Evaluation of the impact of preoperative values of hyaluronic acid and Type IV collagen on the outcome of patients with hepatocellular carcinoma after hepatectomy. J. Nippon Med. Sch.85(4), 221–227 (2018).
   PubMed Web of Science ®Google Scholar
• KocabayogluP, Piras-StraubK, GerkenG, PaulA, HerzerK. Expression of fibrogenic markers in tumor and tumor-surrounding tissue at time of transplantation correlates with recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann. Transplant.22, 446–454 (2017).
   PubMed Web of Science ®Google Scholar
• KawaiS, KuboS, TsukamotoTet al.Serum concentration of Type IV collagen 7S domain as a marker for increased risk of recurrence after liver resection for hepatocellular carcinoma. Dig. Surg.20(3), 201–208 (2003).
   PubMed Web of Science ®Google Scholar
• UenoT, HashimotoO, SugawaraHet al.Serum carboxy-terminal cross-linked telopeptide of Type I collagen reflects bone metastasis in hepatocellular carcinoma. Int. J. Oncol.13(2), 297–303 (1998).
   PubMed Web of Science ®Google Scholar
• MurawakiY, IkutaY, NishimuraY, KodaM, KawasakiH. Serum markers for fibrosis and plasma transforming growth factor-β1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J. Gastroenterol. Hepatol.11(5), 443–450 (1996).
   PubMed Web of Science ®Google Scholar
• Hernandez–GeaV, ToffaninS, FriedmanSL, LlovetJM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology144(3), 512–527 (2013).
   PubMed Web of Science ®Google Scholar
• KarsdalMA, NielsenMJ, SandJMet al.Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev. Technol.11(2), 70–92 (2013).
   PubMed Web of Science ®Google Scholar
• LeemingDJ, Bay-JensenAC, VassiliadisE, LarsenMR, HenriksenK, KarsdalMA. Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development. Biomarkers16(1366–5804), 193–205 (2011).
   PubMedGoogle Scholar
• NielsenMJ, KazankovK, LeemingDJet al.Markers of collagen remodeling detect clinically significant fibrosis in chronic hepatitis C patients. PLoS ONE10(1932–6203), e0137302 (2015).
   PubMedGoogle Scholar
• LeemingDJ, KarsdalMA, ByrjalsenIet al.Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment. Pharmacol.Ther.38(1365–2036), 1086–1096 (2013).
   PubMedGoogle Scholar
• DanielsSJ, LeemingDJ, EslamMet al.ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology69(3), 1075–1086 (2019).
   PubMed Web of Science ®Google Scholar
• NielsenMJ, VillesenIF, GudmannNSet al.Serum markers of Type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients. Sci. Rep.9(1), 14857 (2019).
   PubMedGoogle Scholar
• BoyleM, TiniakosD, SchattenbergJMet al.Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports1(3), 188–198 (2019).
   PubMedGoogle Scholar
• VeidalSS, KarsdalMA, NawrockiAet al.Assessment of proteolytic degradation of the basement membrane: a fragment of Type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair4(1755–1536), 22 (2011).
   PubMedGoogle Scholar
• SunS, HenriksenK, KarsdalMA, ByrjalsenI, RittwegerJ. Collagen Type III and VI turnover in response to long-term immobilization. PLoS ONE10(12), e0144525 (2015).
   PubMed Web of Science ®Google Scholar
• SunK, ParkJ, KimM, SchererPE. Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment. Diabetologia60(1), 24–29 (2017).
   PubMed Web of Science ®Google Scholar
• HeumüllerSE, TalantikiteM, NapoliMet al.C-terminal proteolysis of the collagen VI α3 chain by BMP-1 and proprotein convertase(s) releases endotrophin in fragments of different sizes. J. Biol. Chem.294(37), 13769–13780 (2019).
   PubMed Web of Science ®Google Scholar
• LiX, ZhaoY, ChenCet al.Critical role of matrix metalloproteinase 14 in adipose tissue remodeling during obesity. Mol. Cell. Biol.40(8), (2020).
   Web of Science ®Google Scholar
• TangkijvanichP, AnukulkarnkusolN, SuwangoolPet al.Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol.31(4), 302–8 (2000).
   PubMed Web of Science ®Google Scholar
• GallePR, FoersterF, KudoMet al.Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int.39(12), 2214–2229 (2019).
   PubMed Web of Science ®Google Scholar
• SunK, ParkJ, GuptaOTet al.Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun.5, 3485 (2014).
   PubMed Web of Science ®Google Scholar
• KarsdalMA, HenriksenK, GenoveseFet al.Serum endotrophin identifies optimal responders to PPARγ agonists in Type 2 diabetes. Diabetologia60(1), 50–59 (2017).
   PubMed Web of Science ®Google Scholar
• BuD, CreweC, KusminskiCMet al.Human endotrophin as a driver of malignant tumor growth. JCI Insight5(9), e125094 (2019).
   PubMedGoogle Scholar
• LiaoX, YuL, LiuXet al.Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma. Cancer Manag. Res.10, 953–967 (2018).
   PubMed Web of Science ®Google Scholar
• LaiKKY, ShangS, LohiaNet al.Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet.7(6), e1002147 (2011).
   PubMed Web of Science ®Google Scholar
• SchuppanD. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J.Hepatol.13(Suppl. 3), S17–S25 (1991).
   PubMedGoogle Scholar
• SchuppanD, StölzelU, OesterlingC, SomasundaramR. Serum assays for liver fibrosis. J. Hepatol.22(Suppl. 2), 82–88 (1995).
   PubMedGoogle Scholar
• SchuppanD, RühlmannT, HahnEG. Radioimmunoassay for human Type VI collagen and its application to tissue and body fluids. Anal. Biochem.149(1), 238–247 (1985).
   PubMed Web of Science ®Google Scholar
• ShahinM, SchuppanD, WaldherrRet al.Serum procollagen peptides and collagen Type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology15(4), 637–644 (1992).
   PubMed Web of Science ®Google Scholar
• GerlingB, BeckerM, StaarD, SchuppanD. Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N. Engl. J. Med.336(22), 1611–2 (1997).
   PubMed Web of Science ®Google Scholar
• StickelF, UrbaschekR, SchuppanDet al.Serum collagen Type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig. Dis. Sci.46(0163–2116), 2025–2032 (2001).
   PubMedGoogle Scholar
• LuoY, OseiniA, GagnonRet al.An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci. Rep.8(1), 1–9 (2018).
   PubMedGoogle Scholar
• DoldL, NielsenMJ, PraktiknjoMet al.Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART. PLoS ONE14(7), e0219526 (2019).
   PubMed Web of Science ®Google Scholar
• JensenC, NielsenSH, EslamMet al.Cross-linked multimeric pro-peptides of Type III collagen (PC3X) in hepatocellular carcinoma –a biomarker that provides additional prognostic value in AFP positive patients. J. Hepatocell. Carcinoma7, 301–313 (2020).
   PubMed Web of Science ®Google Scholar